Proteostasis Therapeutics to Initiate First Ever Personalized Medicine-Based Clinical Trial, CHOICES, in European CF Patients with Genotypes Ineligible for Approved CFTR Modulators

Stock Information for Proteostasis Therapeutics Inc.

Loading

Please wait while we load your information from QuoteMedia.